At the heart of this pioneering work lies the intricate manipulation of the ubiquitin-proteasome system (UPS), which maintains cellular proteostasis by selectively tagging proteins for degradation. Traditionally, targeted protein degradation has relied on bivalent molecules called PROTACs that bridge a target protein and a single E3 ubiquitin ligase, thus mediating ubiquitination and subsequent proteasomal elimination. However, the challenge of balancing specificity, potency, and tunability in such approaches has often limited their therapeutic utility and scope.

The novel concept introduced by Spiteri, Segal, Correa-Sáez, and colleagues transcends these constraints by employing monovalent small molecules that can tether two different E3 ligases simultaneously—an elegant solution that expands the molecular toolbox available for inducible protein degradation. Unlike conventional bivalent degraders that form dual binding pockets, these monovalent degraders rely on carefully designed ligands that leverage cooperative E3 ligase engagement to fine-tune degradation kinetics and substrate selectivity.

SMARCA2 and SMARCA4, the focal targets of this study, are ATP-dependent chromatin remodelers integral to the SWI/SNF complex. Dysregulation of these proteins is implicated in a multitude of cancers, making their controlled degradation a highly sought-after objective in precision oncology. Notably, SMARCA2/4 exhibit partial redundancy in function, and the ability to differentially modulate their levels offers a therapeutic window with minimal off-target cytotoxicity.

Utilizing sophisticated chemical synthesis and biophysical characterization, the research team crafted a suite of monovalent degraders capable of recruiting Cereblon (CRBN) and von Hippel–Lindau (VHL) E3 ligases concurrently. This dual-ligase recruitment was validated through rigorous cellular assays, which revealed a tunable degradation profile contingent on ligand structure and concentration. By modulating these parameters, researchers demonstrated precise control over SMARCA2 and SMARCA4 turnover, opening avenues for programmable degradation regimens.

Mechanistically, the study elucidates how simultaneous engagement of two E3 ligases enhances the formation of a ternary complex that stabilizes the proximity of the ubiquitination machinery and the target protein. This phenomenon markedly increases ubiquitin transfer efficiency, thereby accelerating proteasomal recognition and degradation. Importantly, the dual-ligase approach mitigates common pitfalls associated with single-ligase systems such as ligand resistance, off-target effects, and limited degradation depth.

Beyond the biochemical insights, the researchers harnessed cryo-electron microscopy and molecular dynamics simulations to map the architecture of the ternary complex formed by the monovalent degrader, SMARCA2/4, and the paired E3 ligases. These structural studies illuminated critical interactions driving complex stability and informed iterative design cycles for optimized degrader molecules with enhanced pharmacological properties.

One remarkable aspect of this work is the strategic exploitation of E3 ligase interplay to create a modular degradation platform. The team demonstrated that swapping VHL with other E3 ligases, such as MDM2 or RNF4, altered degradation outcomes, underscoring the versatility and adaptability of this approach across diverse biological contexts. This modularity heralds the advent of a new generation of precision degraders tailored to the proteomic and pathophysiological landscape of individual diseases.

The translational potential of dual E3 ligase-recruiting monovalent degraders was evaluated in cancer cell lines harboring SMARCA2/4-dependent proliferative phenotypes. Treatment with these degraders led to pronounced growth inhibition and apoptosis, validating the therapeutic relevance of this targeted degradation strategy. Moreover, the tunability feature enables dosage-dependent control, mitigating toxicity while maximizing efficacy—a significant leap forward compared to traditional inhibitors.

From a broader perspective, this innovative approach addresses long-standing challenges in drug discovery, including the notoriously “undruggable” nature of protein complexes involved in chromatin remodeling. By leveraging the cell’s intrinsic proteolytic machinery more robustly, monovalent dual degraders pave the way for chemically induced proximity methods that transcend classical binding site limitations, enabling precise intervention on protein function via degradation rather than inhibition.

The implications of this work extend beyond oncology, as the ability to harness multiple E3 ligases in a coordinated manner offers a rich framework for targeting proteins implicated in neurodegeneration, immune dysregulation, and metabolic disorders. The authors speculate that further refinement and expansion of the ligand repertoire could yield bespoke degraders capable of sculpting the cellular proteome with exquisite specificity.

Critically, the design principles uncovered in this study establish foundational knowledge for the rational development of next-generation molecular glues and degraders. The prospect of fine-tuning protein degradation pathways unveils new modalities for overcoming drug resistance mechanisms, as multiplexed E3 recruitment may circumvent mutations that abrogate single-ligase engagement.

Looking forward, the authors advocate for integrating chemical synthesis with high-throughput screening and computational modeling to accelerate the discovery of diverse dual-ligase degraders. This multidisciplinary strategy holds promise for expanding the druggable proteome and transforming therapeutic landscapes.

In summary, the elucidation of monovalent degraders capable of dual E3 ligase recruitment signifies a paradigm shift in targeted protein degradation. This technology not only refines our molecular control toolkit but also ignites fresh hope for conquering diseases driven by recalcitrant protein targets with complex biological roles.

By marrying chemical ingenuity with structural biology and systems pharmacology, the work of Spiteri and colleagues redefines how we manipulate intracellular protein fate. As therapeutic pipelines evolve toward precision degradation, dual-ligase monovalent degraders stand poised to revolutionize medicine, offering nuanced strategies adaptable to the molecular intricacies of disease.

Amid the burgeoning field of proteolysis-targeting therapeutics, this breakthrough highlights the importance of conceptual and technological innovation in surmounting biological complexity. The journey from molecular design to clinical utility is just beginning, yet the foundations laid here provide a robust scaffold on which future translational success stories will undoubtedly be built.

Subject of Research: Development of monovalent degraders capable of recruiting two distinct E3 ubiquitin ligases simultaneously for tunable degradation of SMARCA2 and SMARCA4 chromatin remodelers.

Article Title: Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation.

Article References:
Spiteri, V.A., Segal, D., Correa-Sáez, A. et al. Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02224-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02224-y

Targeted protein degradation has emerged as a formidable tool in medicinal chemistry, spearheaded by technologies such as PROTACs (proteolysis-targeting chimeras) that leverage the cell’s ubiquitin-proteasome system. Historically, these bifunctional molecules recruit E3 ubiquitin ligases to label the protein of interest with ubiquitin chains, prompting proteasomal recognition and degradation. While successful, reliance on the limited repertoire of E3 ligases has posed limitations in target scope and tissue specificity. Casasampere et al. disrupt this paradigm by designing small molecule chimeras capable of directly engaging the 26S proteasome, the cellular machinery responsible for the final proteolytic step, bypassing some intrinsic complexities of the ubiquitination step.

The 26S proteasome is an ATP-dependent proteolytic complex renowned for its role in degrading polyubiquitinated proteins, maintaining proteostasis, and regulating cell cycle progression and signal transduction. Traditionally viewed as an untargetable cylindrical protease core complex, the 26S proteasome consists of a 20S core particle capped by 19S regulatory particles that recognize substrates, unfold them, and translocate them into the proteolytic chamber. Casasampere’s team engineered a new class of bifunctional molecules that physically tether the target protein directly to specific proteasomal subunits, effectively bypassing ubiquitination. This bold strategy introduces a direct degradation modality, contrasting with the classic hop-on-hop-off ubiquitin cascades.

The design principles hinge on a modular synthetic approach. One end of the chimera molecule binds with high affinity to the protein of interest, while the other interacts specifically with binding pockets on the 19S regulatory particle or accessory subunits instrumental in substrate recognition. This dual engagement coaxed the proteasome to selectively process the tethered protein, overcoming the proteasome’s usual substrate selectivity constraints. By strategically engineering linker length and molecular geometry, the researchers demonstrated precise spatial orientation essential for degradation efficacy, verified through biochemical assays and single-particle cryo-electron microscopy imaging.

Experimental validation was conducted across diverse cell lines, involving target proteins traditionally considered “undruggable” by classical PROTACs. The team was able to induce robust degradation of proteins implicated in oncogenic signaling, such as transcription factors and scaffold proteins lacking suitable E3 ligase recruitment motifs. Importantly, these effects were proteasome-dependent, as co-treatment with proteasome inhibitors completely abrogated the degradation signal, confirming mechanism specificity. Time-course studies demonstrated rapid kinetics of degradation, offering a therapeutic window advantage over conventional approaches.

Mechanistically, this approach promises more direct manipulation of the degradation endpoint in the proteostasis pathway, reducing reliance on endogenous cellular factors often limiting traditional targeted degradation therapies. The strategy might circumvent resistance mechanisms related to E3 ligase expression or function loss, a known challenge in the clinical translation of ubiquitin-dependent chimeras. Additionally, by targeting the proteasome, this technique harnesses a cellular node with ubiquitous presence and invariant activity across cell types, potentially allowing broader tissue applicability.

On the molecular level, Casasampere and colleagues revealed that tethering the substrate to proteasomal receptors triggers allosteric conformational changes heightening substrate engagement and unfolding efficiency, key steps facilitating proteolysis. High-resolution structural biology coupled with mutagenesis provided insights into binding interfaces and dynamic conformational states, advancing fundamental understanding of proteasomal plasticity. Such detailed mechanistic elucidation forms a critical foundation for rationally designing future chimeras with enhanced selectivity and potency.

From a drug development perspective, this approach opens avenues for tackling complex diseases with pathogenic proteins previously inaccessible by small molecules or biologics. Proteins involved in neurodegenerative diseases, for instance, often form insoluble aggregates resistant to cellular clearance. Direct recruitment of such aggregates to the proteasome could enhance proteolytic degradation, alleviating toxicity. Furthermore, rapidly degrading oncogenic drivers might lead to improved cancer therapeutics with diminished side effects, as transient target engagement mitigates off-target interactions common in inhibitor-based drugs.

Moreover, Casasampere’s team identified key chemical scaffolds amenable to large-scale medicinal chemistry optimization, laying groundwork for drug-like properties compatible with in vivo applications. Their initial pharmacokinetic and toxicity assays in animal models revealed favorable systemic exposure and minimal off-target effects, validating therapeutic potential. The versatility of this platform suggests adaptability not only for intracellular targets but potentially for extracellular or membrane-bound proteins through cell-penetrant chimera designs.

Complementing current targeted degradation technologies, this proteasome-directed approach could integrate synergistically with emerging modalities like molecular glues or lysosome-targeted strategies, enhancing combinatorial regimens that maximize protein clearance. As the field of targeted protein degradation matures rapidly, innovations like these will likely catalyze a new generation of personalized and precision medicines, accelerating the bench-to-bedside timeline for previously elusive molecular targets.

The implications of this research extend to understanding proteasomal pathology itself. Aberrant proteasome function is implicated in numerous diseases, including cancer and neurodegeneration. By providing molecular handles to modulate proteasomal substrate selection, future therapeutics might also rectify dysregulated proteostasis, restoring healthy cell physiology. This dual capacity to degrade harmful proteins while modulating proteasome activity portends a transformative therapeutic landscape.

In conclusion, Casasampere, Carneros, Roda, and their collaborators have elegantly redefined the contours of targeted protein degradation, pioneering direct proteasomal engagement through small molecule chimeras. This paradigm-shifting approach surmounts critical limitations of existing methods and unlocks a panoply of previously inaccessible protein targets. Their work marks a seminal advance at the convergence of chemical biology, structural biochemistry, and drug discovery, guaranteed to ignite further research and clinical translation in the coming years. The field now eagerly awaits expanded biological validation, clinical trials, and broad adoption of this proteasome-centered degradation technology as a staple of next-generation therapeutics.

Subject of Research:
Targeted protein degradation via small molecule chimeras directly engaging the 26S proteasome.

Article Title:
Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome.

Article References:
Casasampere, M., Carneros, H., Roda, T. et al. Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71132-5

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41467-026-71132-5

Keywords:
Targeted protein degradation, 26S proteasome, small molecule chimeras, proteolysis-targeting, chemical biology, proteostasis, structural biochemistry, drug discovery, PROTAC alternatives, ubiquitin-independent degradation